Reversing the aberrant biochemical output of oncogenic Ras proteins is one of the great
challenges in cancer therapeutics; however, it is uncertain which Ras effectors are required …

Despite the well-established role of oncogenic RAS in promoting tumor formation, whether
and how wild-type (WT) Ras inhibits tumorigenesis under physiological conditions remains …

The role of hyperactive RAS signaling is well established in myeloid malignancies but less
clear in T-cell malignancies. The Kras2 LSL Mx1-Cre (KM) mouse model expresses …

Mutations in KRAS are prevalent in human cancers and universally predictive of resistance
to anticancer therapeutics. Although it is widely accepted that acquisition of an activating …

Oncogenic K-Ras proteins, such as K-RasG12D, accumulate in the active, guanosine
triphosphate (GTP)–bound conformation and stimulate signaling through effector kinases …

When overexpressed in primary erythroid progenitors, oncogenic Ras leads to the
constitutive activation of its downstream signaling pathways, severe block of terminal …

RAS mutations are common in myeloid malignancies; however, it is not known whether
oncogenic RAS can initiate leukemia. We show that expressing mutant K-RasG12D protein …

Ras proteins are critical nodes in cellular signaling that integrate inputs from activated cell
surface receptors and other stimuli to modulate cell fate through a complex network of …

Background/Aims: It has been demonstrated that KRAS mutations represent about 90% of
cancer-associated mutations, and that KRAS mutations play an essential role in neoplastic …

Members of the family of RAS proto-oncogenes, discovered just over 40 years ago, were
among the first cancer-initiating genes to be discovered. Of the three RAS family members …